Successful Resection of Retrobulbar Carcinosarcoma without Recurrence: A Case Report

Chun-Hao Huang 1,2, Lung-Chi Lee 2, Hong-Wei Gao 3,4, Yi-Hao Chen 2 and Ke-Hung Chien 2,*

1 Department of Ophthalmology, Taichung Armed Forces General Hospital, Taichung City 41168, Taiwan; fun_creater@hotmail.com
2 Department of Ophthalmology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; kidday0205@gmail.com (L.-C.L.); doc30879@mail.ndmctsgh.edu.tw (Y.-H.C.)
3 Department of Pathology, Tri-Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan; doc31796@gmail.com
4 Department of Pathology, Tungs’ Taichung Metroharbor Hospital No. 699, Section 8, Taiwan Boulevard, Wuchi District, Taichung City 43503, Taiwan
* Correspondence: yred8530@gmail.com; Tel.: +886-2-87923311

Abstract: Carcinosarcomas are biphasic tumors comprising carcinoma and sarcoma components that occur in many tissues but are rarely found in the orbit. A 70-year-old male presented to the ophthalmic clinic with progressive proptosis, having decreased vision in the left eye for 8 months. On examination, severe exophthalmos and lagophthalmos with limited extraocular movement were noted. Orbital computed tomography scans revealed a large, well-defined, heterogeneously enhanced mass in the left retrobulbar orbital cavity. The tumor was completely resected, and the pathological examination revealed a carcinosarcoma. The prognosis was excellent without local recurrence at 48 months postoperatively. Thus, when considering treatment for effective management of such tumors, tumor resection followed by radiotherapy or chemotherapy is highly recommended.

Keywords: orbital carcinosarcoma; tumor resection; radiotherapy; recurrence

1. Introduction

Carcinosarcoma, also referred to as a true malignant mixed tumor, is a biphasic tumor with carcinoma and sarcoma components. A monoclonal origin is considered with myoepithelial cells to be the most likely candidate for common stem cells [1]. Carcinosarcomas occur in many tissues, including the uterus [2,3], bladder [4], skin [5], gastrointestinal tract [6,7], lungs [8], and organs of the head, including the salivary gland [1], lacrimal gland [9], and paranasal sinuses [10]. There are five previously reported cases of primary orbital carcinosarcoma [9–12], and only one case showed no recurrence for 10 months postoperatively. Although it is aggressive and exhibits both local tissue invasion and metastasis, we report the successful treatment of an orbital primary carcinosarcoma using total excision and radiotherapy without recurrence 48 months following treatment.

2. Case Report

A 70-year-old Asian male presented to our department with progressive proptosis. He complained of decreased vision in the left eye for 8 months. The patient had no known systemic disease and had undergone cataract surgery in his left eye 3 years previously.

On examination, the presenting uncorrected visual acuity (VA) was 6/6 in the right eye and counting fingers at 30 cm in the left eye. Intraocular pressure (IOP) was 13 mmHg and 31 mmHg in the right and left eye, respectively. The relative afferent pupillary defect was negative in both eyes.

Evidence of exophthalmos, hypotropia, and lagophthalmos of the left eye (Figure 1) was noted with Hertel values of 20 mm and 27 mm in the right and left eye, respectively.
Extraocular movement was limited in the left eye, especially in the medial gaze position; slit-lamp examination of this eye revealed exposure keratopathy induced by lagophthalmos.

Figure 1. General appearance shows exophthalmos and lagophthalmos of the left eye.

The computed tomography scan of the orbit revealed a heterogeneously enhancing mass in the left retrobulbar orbital cavity approximately $3.7 \times 2.5 \times 2.5$ cm in size involving the frontal bone and extending to the left frontal sinus, causing compression of the left superior rectus, lateral rectus, and inferior rectus muscles, as well as anterior and downward displacement of the left eyeball resulting in exophthalmos (Figure 2).

Figure 2. Orbital computed tomography scan reveals a heterogeneously enhancing mass (red arrows) in the left retrobulbar orbital cavity: (A) Axial plane; (B) coronal plane; (C) sagittal plane.
Lateral orbitotomy was performed to access the retrobulbar space. Frozen sections revealed malignancy accompanied by infiltrating anaplastic spindle tumor cells that had hyperchromatic, pleomorphic nuclei exhibiting frequent mitoses at a distance of 1 mm from the nearest surgical margin. A heterogeneous tumor, measuring approximately 4.0 × 3.0 × 3.0 cm, was carefully dissected, and total resection was performed from the retrobulbar space.

Pathological examination revealed a carcinosarcoma (Figure 3A) characterized by mixed adenocarcinoma and sarcomatous components (Figure 3B) showing pleomorphic and hyperchromatic tumor cells, atypical mitoses, and focal tumor necrosis. The glandular tumor cells and focal sarcomatous cells were positive for pan-cytokeratin staining (Figure 3C). Immunohistochemical staining for vimentin demonstrated a negative result for the glandular tumor cells and positive immunoactivity for the sarcomatous component (Figure 3D).

The patient was subsequently referred to a radio-oncologist for systemic survey and radiation therapy. Although positron emission tomography images revealed no metabolic evidence of systemic malignancy 1 month following the operation, the patient received adjuvant radiation therapy owing to the high local recurrence and distant metastasis rates.
Two months following surgical resection, the patient underwent intensity-modulated radiation therapy over a course of 21 sessions during which the tumor bed and left orbit were subjected to a total dose of 40 Gy (195 cGy per fraction) using 6 MV photons, 5 times a week. The patient was originally scheduled to receive a total dose of 50 Gy over 26 sessions of radiation therapy; however, the treatment was terminated early owing to intolerance to its side effects including dry eye and conjunctivitis. Orbital magnetic resonance imaging and bone scan was performed postoperatively at 3 months and 12 months and yearly thereafter, which revealed no local recurrence of the tumor at 48 months postoperatively. At the last follow-up, 48 months following the tumor resection, the VA remained counting fingers at 30 cm, and the IOP was 13 mmHg in the left eye.

3. Discussion

Carcinosarcoma, a true malignant mixed tumor, is an intermixed biphasic tumor with carcinomatous (malignant epithelial) and sarcomatous (mesenchymal) components. Two theoretical hypotheses have been proposed to explain the histogenesis of these tumors. The first is the multiclonal hypothesis (convergence hypothesis), which supports that the tumors originate from two or more stem cells, the epithelial and mesenchymal components, and should be considered to be a type of collision tumor. The second is the monoclonal hypothesis (divergence hypothesis), which proposes that the tumors stem from a single totipotent stem cell that differentiates into separate epithelial and mesenchymal components. The findings of a study by Thompson et al. showed that six carcinosarcomas from different organs, including the uterus, breast, lung, and gastrointestinal tract demonstrated monoclonal origin from common totipotent progenitor cells [13], which concurred with the monoclonal hypothesis.

Nevertheless, the convergence theory (sarcoma derived from metaplastic transformation of the carcinoma) has also been favored over the combination theory (both components stemmed from the single stem cell clone) in carcinosarcomas of the female genital tract [14], including the uterus [15] and ovary [16], as well as that of the salivary gland [17]. The transformation of carcinoma to sarcoma in these tumors resulted in sarcomatoid carcinomas, which were then termed carcinosarcomas when they demonstrated well-defined differentiation to sarcomatous tissues. The sarcoma and carcinoma components of these tumors both shared the same genetic alteration and were monoclonal, which has been demonstrated in patterns of clonality, genomic analysis, and loss of heterozygosity [18].

There are three types of malignant mixed tumors, the most common type of which is carcinoma ex pleomorphic adenoma, which arises from a pre-existing pleomorphic adenoma. The second type is metastasizing mixed tumor that has benign-appearing epithelial and stromal components, and the third is carcinosarcoma, a true malignant mixed tumor [16] that is extremely rare and has both malignant epithelial and stromal elements. In our case, the tumor could have originated from a benign mixed tumor (pleomorphic adenoma) and subsequently transformed into a carcinosarcoma [19], which is rare. Pleomorphic adenomas that are commonly observed in the salivary gland are benign tumors that carry a risk of malignant transformation of approximately 1.5% in 3 years and 9.5% in 15 years since the time of tumor occurrence [17]. While many authors have assumed that myoepithelial cells were common progenitor cells of tumors, including those of the breast [20] and salivary glands [21], others have been unable to identify this type of cell as a common progenitor [22]. Risk factors for the transformation of urothelial carcinoma into carcinosarcoma, including previous radiation therapy, chemotherapy (e.g., cyclophosphamide), or other conditions that cause cell replication abnormalities, have been reported [23].

Carcinosarcoma of the orbits can be of either primary or metastatic origin. Metastases of carcinosarcomas to the parotid gland [24], breast, prostate, lung [25], and uterus [26] have previously been reported. A study reviewing carcinosarcomas of the maxillary and ethmoid sinuses, with extension into the orbits, has been conducted [10]. Furthermore, a
case of recurrent cutaneous carcinosarcoma of a previously resected basal cell carcinoma originating from the medial canthal region has also been reported [27].

Five case reports describing primary carcinosarcomas arising in the orbit have been reported [9–12], of which only three case reports provided sufficient evidence for the existence of a carcinosarcoma. Among the five cases, one patient showed no evidence of recurrence 10 months following surgical resection and heavy particle beam therapy [9], one patient refused surgery and died 13 months after symptom onset [10], another patient developed lung metastases [12], one patient was lost to follow-up following surgical resection [10], and no follow-up information was available for the final case [11]. Our case has the longest documented survival time of 48 months, with no evidence of recurrence following total surgical resection and subsequent radiotherapy.

Further, the tumor in one previous case arose from a pleomorphic adenoma of the lacrimal gland [9] and those in two patients arose in the accessory lacrimal glands and submucosal glands in the area of the lacrimal sac [10]. In another two patients, the tumors originated from the lacrimal glands [11,12], although sufficient details regarding these were not available. Although the tumor in our case appeared to arise from a pleomorphic adenoma of the lacrimal gland, based on the histopathological features, it could have originated in the left frontal sinus. Among the patients of these previous cases, four were female and the sex of one was not reported [9–12]; ours was the only case pertaining to a male patient.

Owing to the rarity of orbital carcinosarcomas, there is no consensus on the management and prognosis of such tumors, and prospective trials have not yet been performed. Based on the reviews on uterine carcinosarcomas, the recommended mode of management is complete surgical resection with subsequent systemic chemotherapy, including para-platin, cisplatin, ifosfamide, and paclitaxel, in patients in both early and advanced stage diseases [3]. While no survival benefit has been reported with the use of adjuvant radiotherapy, it decreases local recurrence [28]. However, in patients with stage I and II uterine carcinosarcoma who did not undergo lymph node dissection, there was a 21% reduction in death among those who underwent radiotherapy [29]. The primary treatment for ovarian carcinosarcoma is cytoreductive surgery, followed by platinum-based chemotherapy, usually carboplatin-paclitaxel [3]. Cases of carcinosarcoma in the paranasal sinus [10], salivary gland [30], esophagus [31], and urinary bladder [4] treated with surgical resection combined with radiotherapy or chemotherapy have also been reported, although there is still a lack of consensus on the mode of therapy owing to the limited number of cases. Orbital carcinosarcoma is a rare disease entity. Although it can be successfully treated, as in our case, a consensus on the treatment cannot be established due to the small number of cases. Future research on the genetic, molecular signaling pathways, and treatment responses of these tumors, incorporated from different body parts should be considered. Ideally, further well-designed nonrandomized studies should be performed with tumor resection following either chemotherapy, radiotherapy, or both.

4. Conclusions

Carcinosarcomas are rare but aggressive tumors that carry a risk of recurrence and often metastasize. When they occur in the orbits, they may invade the intracranial cavity, resulting in an increased mortality rate. We present a case of rare primary orbital carcinosarcoma that was successfully treated with surgical resection and radiotherapy. Therefore, the therapy of choice for such tumors occurring in different body tissues should be tumor resection for staging and possibly cytoreduction, followed by radiotherapy or chemotherapy. Physicians should be aware of the clinical presentation of this rare entity to ensure aggressive and successful medical management.
Author Contributions: Conceptualization, C.-H.H. and K.-H.C.; methodology, L.-C.L.; validation, C.-H.H., H.-W.G. and K.-H.C.; formal analysis, H.-W.G.; investigation, C.-H.H. and K.-H.C.; resources, Y.-H.C.; writing—original draft preparation, C.-H.H.; writing—review and editing, K.-H.C.; visualization, L.-C.L.; supervision, K.-H.C.; project administration, C.-H.H. and K.-H.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Tri-Service General Hospital approved this study (TSGHIRB no. C202105087 on 1 May 2021).

Informed Consent Statement: Informed consent was obtained from the patient.

Conflicts of Interest: The authors declare no conflict of interest.

Acknowledgments: The authors would like to thank the patient for his participation in this study.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Götte, K.; Riedel, F.; Coy, J.F.; Spahn, V.; Hörmann, K. Salivary gland carcinosarcoma: Immunohistochemical, molecular genetic and electron microscopic findings. Oral Oncol. 2000, 36, 360–364. [CrossRef]
2. Cantrell, L.A.; Blank, S.V.; Duska, L.R. Uterine carcinosarcoma: A review of the literature. Gynecol Oncol. 2015, 137, 581–588. [CrossRef] [PubMed]
3. Berton-Rigaud, D.; Devouassoux-Shisheboran, M.; Ledermann, J.A.; Leitao, M.M.; Powell, M.A.; Poveda, A.; Beale, P.; Glasspool, R.M.; Creutzberg, C.L.; Harter, P.; et al. Gynecologic Cancer Intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int. J. Gynecol. Cancer 2014, 24, 555–560. [CrossRef] [PubMed]
4. Basibuyuk, I.; Topaktas, R.; Elbir, F. Bladder carcinosarcoma: A case report with review of the literature. Arch. Ital. Urol. Androl. 2017, 89, 240–242. [CrossRef] [PubMed]
5. Biernat, W.; Kordek, R.; Liberski, P.P.; Wozniak, L. Carcinosarcoma of the skin. Case report and literature review. Am. J. Dermatopathol. 1996, 18, 614–619. [CrossRef]
6. Madan, A.K.; Long, A.E.; Weldon, C.B.; Jaffe, B.M. Esophageal carcinosarcoma. J. Gastrointest. Surg. 2001, 5, 414–417. [CrossRef]
7. Weidner, N.; Zekan, P. Carcinosarcoma of the colon. Report of a unique case with light and immunohistochemical studies. Cancer 1986, 58, 1126–1130. [CrossRef]
8. Koss, M.N.; Hochholzer, L.; Frommelt, R.A. Carcinosarcomas of the lung: A clinicopathologic study of 66 patients. Am. J. Surg. Pathol. 1999, 23, 1514–1526. [CrossRef]
9. Takahira, M.; Nakamura, Y.; Shimizu, S.; Minato, H.; Katori, N.; Kobayashi, H.; Nakatani, Y.; Sugiyama, K. Carcinosarcoma of the lacrimal gland arising from a pleomorphic adenoma. Am. J. Ophthalmol. 2005, 140, 337–340. [CrossRef]
10. Prakalapakorn, S.G.; Bernardino, C.R.; Auclaire, P.L.; Grossniklaus, H.E. Carcinosarcoma of the orbit: Report of two cases and review of the literature. Ophthalmology 2008, 115, 2065–2070. [CrossRef]
11. Ni, C.; Kuo, P.K.; Dryja, T.P. Histopathological classification of 272 primary epithelial tumors of the lacrimal gland. Chin. Med. J. (Engl.) 1992, 105, 481–485. [PubMed]
12. Font, R.L.; Smith, S.L.; Bryan, R.G. Malignant epithelial tumors of the lacrimal gland: A clinicopathologic study of 21 cases. Arch. Ophthalmol. 1998, 116, 613–616. [CrossRef] [PubMed]
13. Thompson, L.; Chang, B.; Barsky, S.H. Monoclonal origins of malignant mixed tumors (carcinosarcomas). Evidence for a divergent histogenesis. Am. J. Surg. Pathol. 1996, 20, 277–285. [CrossRef] [PubMed]
14. Sreenan, J.J.; Hart, W.R. Carcinosarcomas of the female genital tract. A pathologic study of 29 metastatic tumors: Further evidence for the dominant role of the epithelial component and the conversion theory of histogenesis. Am. J. Pathol. 1995, 149, 666–674. [PubMed]
15. Wada, H.; Enomoto, T.; Fujita, M.; Yoshino, K.; Nakashima, R.; Kurachi, H.; Haba, T.; Wakasa, K.; Shroyer, K.R.; Tsujimoto, M.; et al. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors. Cancer Res. 1997, 57, 5379–5385. [PubMed]
16. Amant, F.; Vloeberghs, V.; Woestenborghs, H.; Moerman, P.; Vergote, I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol. Oncol. 2003, 90, 372–377. [CrossRef]
17. Harada, H. Histomorphological investigation regarding to malignant transformation of pleomorphic adenoma (so-called malignant mixed tumor) of the salivary gland origin: Special reference to carcinosarcoma. Kurume Med. J. 2000, 47, 307–323. [CrossRef]
18. Fujii, H.; Yoshida, M.; Gong, Z.X.; Matsumoto, T.; Hamano, Y.; Fukunaga, M.; Hruban, R.H.; Gabrielson, E.; Shirai, T. Frequent genetic heterogeneity in the clonal evolution of gynecologic carcinosarcoma and its influence on phenotypic diversity. Cancer Res. 2000, 60, 114–120. [CrossRef]
19. Stephen, J.; Batsakis, J.G.; Luna, M.A.; von der Heyden, U.; Byers, R.M. True malignant mixed tumors (carcinosarcoma) of salivary glands. Oral Surg. Oral Med. Oral Pathol. 1986, 61, 597–602. [CrossRef]
20. Wargotz, E.S.; Norris, H.J. Metaplastic carcinomas of the breast. III. Carcinosarcoma. *Cancer* 1989, 64, 1490–1499. [CrossRef]
21. Nagao, K.; Matsuzaki, O.; Saiga, H.; Sugano, I.; Shigematsu, H.; Kaneko, T.; Katoh, T.; Kitamura, T. Histopathologic studies on carcinoma in pleomorphic adenoma of the parotid gland. *Cancer* 1981, 48, 113–121. [CrossRef]
22. Latkovich, P.; Johnson, R.L. Carcinosarcoma of the parotid gland: Report of a case with cytostatologic and immunohistochemical findings. *Arch. Pathol. Lab. Med.* 1998, 122, 743–746.
23. Sigal, S.H.; Tomaszewski, J.E.; Brooks, J.J.; Wein, A.; LiVolsi, V.A. Carcinosarcoma of bladder following long-term cyclophosphamide therapy. *Arch. Pathol. Lab. Med.* 1991, 115, 1049–1051.
24. Kiratli, H.; Soysal, H.G.; Demir, S. Orbital metastasis and intraocular invasion of malignant mixed tumor (carcinosarcoma) of the parotid gland in a child. *Arch. Ophthalmol.* 2004, 122, 114–118. [CrossRef] [PubMed]
25. Ferry, A.P.; Font, R.L. Carcinosarcoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. *Arch. Ophthalmol.* 1974, 92, 276–286. [CrossRef] [PubMed]
26. Qureshi, S.; Patel, N.A.; Patel, N.; Ghassibi, M.P.; Tse, D.T.; Dubovy, S.R. Metastatic Uterine Carcinosarcoma to the Orbit. *Ophthalmic Plast. Reconstr. Surg.* 2021, 37, e198–e202. [CrossRef] [PubMed]
27. Fernandez, C.; Forrest, P.; Sivalingam, M.; Milman, T.; Ramesh, S.; Shi, W. Exenteration and Adjuvant Radiotherapy for Primary Carcinosarcoma of the Anterior Orbit: A Case Report. *Ophthalmic Plast. Reconstr. Surg.* 2021, 37, e136–e139. [CrossRef] [PubMed]
28. Reed, N.S.; Mangioni, C.; Malmström, H.; Scarfone, G.; Poveda, A.; Pecorelli, S.; Tateo, S.; Franchi, M.; Jobsen, J.J.; Coens, C.; et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). *Eur. J. Cancer* 2008, 44, 808–818. [CrossRef] [PubMed]
29. Wright, J.D.; Seshan, V.E.; Shah, M.; Schiff, P.B.; Burke, W.M.; Cohen, C.J.; Herzog, T.J. The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma. *Am. J. Obstet. Gynecol.* 2008, 199, 536.e1–536.e8. [CrossRef]
30. Gupta, A.; Koochakzadeh, S.; Neskey, D.M.; Nguyen, S.A.; Lentsch, E.J. Salivary Carcinosarcoma: An Extremely Rare and Highly Aggressive Malignancy. *Laryngoscope* 2020, 130, E335–E339. [CrossRef]
31. Chen, S.; Shi, Y.; Lu, Z.; Wang, M.; Cong, L.; Yang, B.; Chen, X.; Cai, J.; Yang, X. Esophageal Carcinosarcoma: Analysis of Clinical Features and Prognosis of 24 Cases and a Literature Review. *Cancer Control* 2021, 28, 10732748211004886. [CrossRef] [PubMed]